Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a ...
07 Oct, 2024 25 Nov, 2024 5:1 For every 1 share held; Holder will receive 5 bonus shares. 11 Mar, 2011 28 Apr, 2011 1:1 For every 1 share held; Holder will receive 1 bonus shares.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback